← All trials
NCT06756308
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 24, 2024
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Jan 2, 2025
- Last posted
- Jan 2, 2025
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- The Leukemia and Lymphoma SocietyCollaborator
- Bristol-Myers SquibbCollaborator
- Memorial Sloan-Kettering Cancer CenterOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.